Document Detail


Recognition of a Natural WT1 Epitope by a Modified WT1 Peptide-specific T-Cell Receptor.
MedLine Citation:
PMID:  23225417     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
Wilms' tumor gene WT1 is highly expressed in leukemia and in various types of solid tumors and exerts an oncogenic function. Thus, WT1 protein is a most promising tumor-associated antigen. We have been successfully performing WT1 vaccination with a 9-mer modified WT1(235) peptide, which has one amino acid substitution (M→Y) at position 2 of 9-mer natural WT1(235) peptide (235-243 a.a.), for close to 700 HLA-A*24:02-positive patients with leukemia or solid tumors. Although vaccination of modified WT1(235) peptide induced natural WT1(235) peptide-recognizing cytotoxic T-lymphocytes (CTLs) and exerted cytotoxic activity towards leukemia and solid tumor cells that expressed the natural WT1(235) peptide (epitope) but not the vaccinated modified WT1(235) peptide (epitope), the molecular basis has remained unclear. In this study, we established a modified WT1(235) peptide-specific CTL clone, we isolated T-cell receptor (TCR) genes from it and transduced the TCR genes into CD8(+) T-cells. The TCR-transduced CD8(+) T-cells produced interferon-γ (IFNγ) and tumor necrosis factor-α (TNFα) in response to stimulation not only with the modified WT1(235) peptide but also with the natural WT1(235) peptide and lysed modified or natural WT1(235) peptide-pulsed target cells and endogenously WT1-expressing leukemia cells in a HLA-A*24:02-restriction manner. These results provided us, for the first time at molecular basis, with a proof-of-concept of modified WT1(235) peptide-based immunotherapy for natural WT1(235) peptide-expressing malignancies.
Authors:
Taichi Tamanaka; Yoshihiro Oka; Fumihiro Fujiki; Akihiro Tsuboi; Akiko Katsuhara; Hiroko Nakajima; Naoki Hosen; Sumiyuki Nishida; Yu-Hung Lin; Sho Tachino; Yoshiki Akatsuka; Kiyotaka Kuzushima; Yusuke Oji; Atsushi Kumanogoh; Haruo Sugiyama
Related Documents :
23480167 - Forming cross-linked peptidoglycan from synthetic gram-negative lipid ii.
6430717 - Structural study of hemoglobin hazebrouck, beta 38(c4)thr----pro. a new abnormal hemogl...
22370557 - The distal c-terminal region of the kcsa potassium channel is a ph-dependent tetrameriz...
24275947 - Relationships between cargo, cell penetrating peptides and cell type for uptake of non-...
11252897 - Intramembrane proteolysis by presenilins.
17292837 - Structure of the histone chaperone asf1 bound to the histone h3 c-terminal helix and fu...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Anticancer research     Volume:  32     ISSN:  1791-7530     ISO Abbreviation:  Anticancer Res.     Publication Date:  2012 Dec 
Date Detail:
Created Date:  2012-12-10     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8102988     Medline TA:  Anticancer Res     Country:  Greece    
Other Details:
Languages:  eng     Pagination:  5201-9     Citation Subset:  IM    
Affiliation:
Department of Functional Diagnostic Science, Osaka University Graduate School of Medicine, 1-7, Yamada-Oka, Suita City, Osaka 565-0871, Japan. sugiyama@sahs.med.osaka-u.ac.jp.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Bevacizumab impairs hepatocyte proliferation after partial hepatectomy in a rabbit model.
Next Document:  Overexpression of CD9 in Human Breast Cancer Cells Promotes the Development of Bone Metastases.